Core Insights - Vaxcyte, Inc. will report its financial results for Q4 and full year 2025 on February 24, 2026, and will host a conference call at 4:30 p.m. ET [1] Company Overview - Vaxcyte is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to combat bacterial diseases [3] - The company is advancing several vaccine candidates, including VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) in Phase 3 and Phase 2 clinical programs, and VAX-24, a 24-valent PCV designed to cover more serotypes than any current infant PCV [3] - Vaxcyte's pipeline also includes VAX-A1, aimed at preventing Group A Strep infections, and VAX-GI, designed to prevent Shigella [4] Technology and Innovation - Vaxcyte utilizes the XpressCF® cell-free protein synthesis platform, licensed from Sutro Biopharma, to produce complex proteins and antigens, enhancing the development of high-fidelity vaccines [4] - The company's approach aims to improve upon standard PCVs by addressing serotypes associated with high case-fatality rates and antibiotic resistance while maintaining coverage of previously circulating strains [3]

Core Insights - Vaxcyte, Inc. will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026 [1] - A live webcast of the event will be available on the company's website, with a replay accessible for 30 days post-conference [2] Company Overview - Vaxcyte is focused on engineering high-fidelity vaccines to combat bacterial diseases, with notable candidates including VAX-31 and VAX-24 [3] - VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 and Phase 2 clinical programs, aimed at preventing invasive pneumococcal disease [3] - VAX-24 is a 24-valent PCV candidate designed to cover more serotypes than any existing infant PCV [3] - The company is also developing VAX-XL, which utilizes advanced conjugation technology to enhance vaccine coverage [3][4] Technology and Innovation - Vaxcyte employs the XpressCF® platform for cell-free protein synthesis, allowing for the production of complex proteins and antigens more efficiently than traditional methods [4] - The pipeline includes VAX-A1, targeting Group A Strep infections, and VAX-GI, aimed at preventing Shigella [4]